A recent CMAJ editorial1 expresses concern that the reclassification of levonorgestrel 0.75 mg (Plan B) as a “behind the counter” product represents a “needless barrier to access.”
The National Association of Pharmacy Regulatory Authorities strongly believes that incorporating pharmacists' counselling in the provision of emergency contraceptives benefits women and the health care system. Pharmacists can play a key role in educating women on the risk of infection associated with unprotected sex, the correct use of barrier and hormonal contraception and the management of side effects of this medication. Women will have the option of visiting a physician or a pharmacist and thus will be able to make their own decision on the initial point of care.
Given the experience in British Columbia2 of a “dramatic rise” in the total use of emergency contraceptives “resulting mainly from pharmacy dispensing” (to quote the CMAJ editorial), it is difficult to understand how consultation with the pharmacist presents a barrier to access. Licensed pharmacists possess the knowledge, skills and professionalism needed to sensitively supply emergency contraception.